Bacterial Genome Editing

Bacterial Genome Editing

Bacteria, a group of highly diverse prokaryotes, play an irreplaceable and crucial role across multiple fields including biotechnology, industrial production, pharmaceutical R&D, and fundamental biological research. Common model and industrial bacterial species mainly include Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Staphylococcus aureus, and various actinomycetes (such as Streptomyces coelicolor, Streptomyces variabilis, etc.).

Bacteria possess unique physiological and metabolic properties along with specific application scenarios, demonstrating significant advantages in different domains:

Escherichia coli : As a classic model prokaryotic microorganism, it is the most widely used recombinant expression host. Its clear genetic background, rapid reproduction rate, and efficient protein expression capabilities establish its core position in the large-scale production of recombinant proteins, metabolic engineering, and fundamental/applied synthetic biology research.

Corynebacterium glutamicum: Belonging to the classic industrial amino acid-producing bacteria, it features a broad substrate spectrum and flexible metabolic regulation. It is not only applicable for the biosynthesis of various high-value-added compounds (e.g., amino acids, vitamins) but also holds significant application potential in food fermentation and the production of pharmaceutical intermediates.

Bacillus subtilis: As a classic Gram-positive model microorganism, its powerful secretory expression capacity and status as a Generally Recognized As Safe (GRAS) strain make it indispensable for the synthesis of industrial enzymes (e.g., amylases, proteases), bio-pesticides, and research into prokaryotic physiological and metabolic mechanisms.

Staphylococcus aureus: A clinically common opportunistic pathogen, it also serves as an important model organism for deciphering bacterial pathogenesis, the evolution of drug resistance, and host-pathogen interactions, providing a key research model for the development of antimicrobial agents.

Actinomycetes: Exhibit diverse application value in pharmaceutical, industrial, and agricultural research. For instance, they are used for the large-scale production of natural secondary metabolites like antibiotics (e.g., streptomycin, tetracycline) and immunosuppressants. They also hold important application prospects in areas such as agricultural biocontrol and the degradation of environmental pollutants.

Service Advantages

(1) High Efficiency and Precision: Based on CRISPR/Cas systems (e.g., Cas9, Cas12a) and traditional homologous recombination (e.g., λ-Red system), editing efficiency is high (surpassing 80% for single-gene edits in most bacteria, reaching up to 100% in some cases). Precise targeting via sgRNA significantly reduces off-target effects and polar effects.

(2) Flexibility and Diversity: Supports various editing modalities including knockout, knock-in, point mutation, and replacement. Services are customizable regarding sgRNA, promoters, and delivery methods (e.g., electroporation, conjugation) to adapt to the physiological characteristics of different bacteria.

(3) Broad Applicability: Covers both Gram-negative and Gram-positive bacteria, applicable to laboratory-standard model strains and complex industrial wild-type strains. Supports scarless (marker-free) sequential editing and marker-free screening.

(4) Controllable Timelines: Project timelines for standard strains are typically 1-3 months (1-2 months for conventional model bacteria like E. coli; 2-3 months for actinomycetes and wild-type strains). Standardized processes ensure reliable results.